Effects of Extended-Release Niacin Added to Simvastatin/Ezetimibe on Glucose and Insulin Values in AIM-HIGH

详细信息    查看全文

• 作者：Ronald B. Goldberg ; MD^a ; Vera A. Bittner ; MD ; MSPH^b ; Richard L. Dunbar ; MD ; MS^c ; Jerome L. Fleg ; MD^d ; George Grunberger ; MD^e ; John R. Guyton ; MD^f ; Lawrence A. Leiter ; MDCM^g ; Ruth McBride ; ScB^h ; ^{ruthm@axioresearch.com" class="auth_mail" title="E-mail the corresponding author} ; Jennifer G. Robinson ; MD ; MPHⁱ ; Debra L. Simmons ; MD ; MS^j ; Carol Wysham ; MD^k ; Ping Xu ; MS^l ; William E. Boden ; MD^m
• 关键词：Clinical trial ; Diabetes ; Extended release niacin ; Glucose and insulin ; Heart disease ; Impaired fasting glucoses
• 刊名：The American Journal of Medicine
• 出版年：2016
• 出版时间：July 2016
• 年：2016
• 卷：129
• 期：7
• 页码：753.e13-753.e22
• 全文大小：265 K

文摘

Niacin is an antidyslipidemic agent that may cause blood sugar elevation in patients with diabetes, but its effects on glucose and insulin values in nondiabetic statin-treated subjects with cardiovascular disease and at high risk for diabetes are less well known.

Methods

This was a prespecified, intent-to-treat analysis of the Atherothrombosis Intervention in Metabolic syndrome with low high-density lipoprotein/high triglycerides: Impact on Global Health outcomes trial which randomized 3,414 participants at 92 centers in the US and Canada to extended-release niacin (ERN) plus simvastatin/ezetimibe (ERN) or simvastatin/ezetimibe plus placebo (Placebo). Baseline and annual fasting glucose and insulin values were measured. Those experiencing an adverse event indicative of diabetes or starting medications for diabetes were considered to have confirmed diabetes. In addition, nondiabetic subjects with 2 annual follow-up glucose measurements were categorized into normal, impaired fasting glucose or newly diagnosed diabetes (presumed or confirmed) states.

Results

Compared with placebo, ERN increased annual fasting glucose from baseline to 1 year in both those with normal (7.9 ± 15.8 vs 4.3 ± 10.3 mg/dL; P < .001) and impaired fasting glucose (4.1 ± 18.7 vs 1.4 ± 14.9; P < .02) and increased insulin levels. Both effects waned over the next 2 years. There were less consistent effects in those with baseline diabetes. There was an increased risk of progressing from normal to presumed or confirmed impaired fasting glucose (ERN 197/336) cases (58.6%) vs placebo 135/325 cases (41.5%; P < .001) over time, but no difference in diabetes development in the 2 treatment groups except in those with normal fasting glucose at baseline.

Conclusions

The addition of ERN to simvastatin/ezetimibe had marginal effects on glycemia in those with diabetes at baseline, and there was a trend toward increased development of new-onset diabetes. In addition, ERN increased the risk of developing impaired fasting glucose, which may have deleterious consequences over time and warrants further study.